Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

Trial ID or NCT#

NCT05224661

Status

recruiting iconRECRUITING

Purpose

Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).

Official Title

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Aged at least 18 years old at time of consent 4. Diagnosed with AML, in complete remission 1. Complete remission (CR) definition per local institutional criteria 2. CR with incomplete hematologic recovery (CRi) is not an exclusion criterion 3. MRD positivity is not an exclusion criterion 5. Undergoing alloHCT 6. Has specimen from time of AML diagnosis available
Exclusion Criteria:
  1. 1. Diagnosis of acute promyelocytic leukemia 2. Prior alloHCT
View All Criteria
Show Less

Investigator(s)

Lori Muffly
Lori Muffly
Hematologist, Blood and marrow transplant specialist, Blood and marrow transplant specialist, Hematologist-Oncologist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Contact us to find out if this trial is right for you.

Contact

Audrey Xu
650-725-1647

SEND MESSAGE

View on ClinicalTrials.gov